Last reviewed · How we verify

NCT05857137

Psychosis TMS Study

Active, enrolled NA Last updated 10 February 2026
What this trial tests

NA trial testing Active TMS in Psychosis in 20 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline
4 April 2023
Primary endpoint
15 April 2026
30 July 2026

Quick facts

Lead sponsorMassachusetts General Hospital
PhaseNA
StatusActive, enrolled
Study typeINTERVENTIONAL
Allocationrandomized
Designcrossover
Maskingdouble
Primary purposebasic science
Enrollment20
Start date4 April 2023
Primary completion15 April 2026
Estimated completion30 July 2026
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Massachusetts General Hospital

Who can join

Adults 18 to 35, any sex, with Psychosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The main goal of this study is to investigate the neural mechanisms of working memory function in patients with early psychosis using Transcranial Magnetic Stimulation (TMS) in conjunction with functional MRI. TMS is a noninvasive method used to modulate brain activity via changing magnetic fields applied over the surface of the scalp.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Active TMS

Trials testing the same drug.

Other recruiting trials for Psychosis

Currently open trials in the same condition.

Other Massachusetts General Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05857137.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing